(redirected from Panretin)


a topical antineoplastic used in the treatment of AIDS-related cutaneous Kaposi's sarcoma.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.



Pharmacologic class: Second-generation retinoid

Therapeutic class: Topical antineoplastic

Pregnancy risk category D


Binds to and activates intracellular retinoid receptor subtypes, regulating expression of genes that control cellular differentiation and proliferation


Topical gel: 0.1%

Indications and dosages

Treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma

Adults: Apply to lesions b.i.d., gradually increasing to t.i.d. or q.i.d. according to individual lesion tolerance


• Hypersensitivity to retinoids or other drug components


Use cautiously in:

• photosensitivity

• concomitant use of insecticides containing diethyltoluamide (DEET)

• elderly patients

• pregnant or breastfeeding patients

• children.


• Apply generous amount of gel to affected area. Let it dry for 3 to 5 minutes before covering with clothing.

Adverse reactions

CNS: paresthesia

Skin: rash, pruritus, exfoliative dermatitis, skin disorder at application site (such as abrasion, burning, blisters, excoriation, scab, cracking, crusting, drainage, eschar, fissure, oozing, peeling, redness, or swelling), edema

Other: pain, increased sensitivity to sunlight or sun lamps


Drug-behaviors. DEET-containing insect repellents: increased adverse reactions to DEET

Patient monitoring

• Monitor patient for serious adverse effects, especially burns caused by exposure to sunlight or sun lamps.

Patient teaching

• Instruct patient to apply generous amount of gel to affected skin area and let dry for 3 to 5 minutes before covering area with clothing.

• Caution patient to avoid applying gel to mucous membranes or to normal skin surrounding lesions.

Inform patient that drug increases sensitivity to sunlight and that exposure to sunlight or sun lamps (even through window glass or on a cloudy day) may cause serious burn of treated areas. Caution him to avoid such exposure.

• Tell patient to avoid insect repellents containing DEET during therapy.

• Emphasize importance of keeping all medical appointments so prescriber can check progress and monitor for unwanted drug effects.

• Advise females of childbearing potential to avoid becoming pregnant while using this drug.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the behaviors mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved
Mentioned in ?
References in periodicals archive ?
On April 1, 2019, announced the acquisition of the global rights to two established medicines, Salagen tablets (pilocarpine hydrochloride) (excluding Japan) and Panretin gel (alitretinoin), from Eisai Inc.
(TSX: ADVZ) has acquired global rights to Salagen and Panretin, two established medicines, from Eisai, Inc., the company said.
Combined, Salagen and Panretin generated approximately USD 13m in revenue in 2018 in the territories where Advanz Pharma will hold the rights.
Global Banking News-April 2, 2019-ADVANZ PHARMA Corp reports acquisition of international rights to Salagen and Panretin
M2 PHARMA-April 2, 2019-ADVANZ PHARMA Corp reports acquisition of international rights to Salagen and Panretin
Eisai obtained exclusive rights for Ontak, Targretin capsules, Targretin gel and Panretin from Ligand.
* We note your schedule on page 187 for the allowances for loss on returns, rebates, chargebacks and other discounts, ONTAK end-customer and Panretin returns.
Tokyo, Japan, Sept 8, 2006 - (JCN) - Eisai has announced that it signed a product acquisition agreement with California-based Ligand Pharmaceuticals for exclusive global rights for their four oncology-related products, ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%.
"The data suggest that practitioners will not run into any trouble in terms of new safety concerns as they treat patients longer and longer" with alitretinoin gel (Panretin), Dr.
* Alitretinoin (Panretin) gel 0.1%, Ligand Pharmaceuticals
M2 EQUITYBITES-April 2, 2019-ADVANZ PHARMA Corp reports acquisition of international rights to Salagen and Panretin
Heyman led the development of Panretin and Targretin, which were approved by the FDA for the treatment of cancer.